SC+ delivers the innovation to underpin self-care haemodialysis
Quanta Dialysis Technologies, today announces that the Company will be exhibiting at the 55th Annual European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Thursday 24th to Sunday 27th May, at the Bella Center in Copenhagen, Denmark at booth number 4.151. Quanta will be showcasing its new look, state-of-the-art personal haemodialysis system, SC+, designed to offer patients flexibility enabling them to fit treatment around everyday life.
Quanta Dialysis Technologies, today announces that the Company has successfully completed a clinical pilot to treat patients in France. Building off its successful UK pilot, this is the first time Quanta's personal haemodialysis system, SC+ has been used outside the UK. The treatments took place over a two-week period with five patients in Hôpital Necker, Paris. The treatments were led by French nurses who were trained by Quanta. These initial treatments in France were in addition to the ongoing pilot study in the UK, which has so far resulted in more than 1,400 successful patient treatments.
Quanta Dialysis Technologies, today announces that the Company will be presenting at the 38th Annual Dialysis Conference (ADC), which runs from 3 to 6 March 2018 at the Marriott Orlando World Center in Florida, USA. Peter Hoyer, Chief Commercial Officer, will provide an update on Quanta's unique small, simple and powerful haemodialysis system, SC+, in the 'Home HD Machines' session chaired by Robert Lockridge, MD, on Sunday 4 March at 2:15pm. The session will include an update on the results of the SC+ Pilot Study, which includes extensive, successful, patient treatments at four NHS Trusts across the UK.
Quanta Dialysis Technologies, today announces that the Company is unveiling its SC+ personal haemodialysis system for market launch next year. Based on clinical experience obtained during Quanta's extensive pilot studies, which included over 1,100 successful patient treatments at four NHS Trusts across the UK, the Company has optimised SC+ for commercial launch. In addition to the small, simple-to-use and powerful features that already set SC+ apart from traditional dialysis machines, Quanta is introducing state-of-the-art technology enhancements that include a new user interface featuring a high resolution screen and improved touch functionality, improvements for usability and capabilities to integrate with digital health solutions.
Quanta Dialysis Technologies, today announces that the Company will be exhibiting at the 10th UK Annual Dialysis Conference, taking place from Thursday 28th to Friday 29th September 2017, at the Lowry Hotel in Manchester, UK. The UK Annual Dialysis Conference theme for 2017 is 'Dialysis fit for the 21st century', which focuses on the challenges, improvements and outcomes faced by dialysis patients and clinicians in the UK. Patients, clinicians and researchers will explore and discuss topics of clinical interest, including effective integrated home dialysis models, clinical challenges in dialysis practice and quality improvement.
Quanta Dialysis Technologies, today announces that the Company will be attending the German Society of Nephrology 9th Annual Congress 2017 (DGFN 2017) taking place from Thursday 14th to Sunday 17th September 2017, at the Congress Center Rosengarten in Mannheim, Germany.
Quanta Dialysis Technologies, today announces that the Company will be exhibiting at the 54th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress which runs from Saturday 3rd June to Tuesday 6th June at the IFEMA Conference Centre in Madrid, Spain at booth number 3.135. Quanta will be showcasing SC+, its easy-to-use, compact, haemodialysis system, offering high performance comparable to conventional devices and compatibility with traditional treatment regimens typically used in-centre. SC+ has been designed to provide flexibility and convenience to dialysis patients empowering them to regain control of their lives.
Quanta Dialysis Technologies is very excited to become part of the global kidney community as it approaches the 2018 commercial launch of its new haemodialysis system -the SC+. Over 64,000 people in the UK are currently being treated for end-stage renal disease and more than 24,000 undergo dialysis treatment to keep them alive. Quanta recognises that what most dialysis patients want is to be able to focus on their families, their work and their lives. Managing dialysis treatment can make that very challenging so there was clearly a need for a machine that is compact and easy to use, enabling greater flexibility and patient independence.
As I write this I am sitting in the desert outside Dubai, about to start a busy day of fun, jumping out of aeroplanes and horse riding in the sand dunes. The only reason I am here now, pursuing life with a passion and living very happily and healthily is because of home dialysis. 20 year's ago my life was turned upside down by an aggressive onset of FSGS. I spent 18 months in Guy's Hospital undergoing treatment including steroids and chemotherapy plus an array of horrible complications. At 14 years old I had my kidneys removed and immediately opted to dialyse myself at home on overnight APD.
Quanta Dialysis Technologies, today announces that the Company will be exhibiting at the British Renal Society Conference 2017, which runs from 26 to 28 April 2017, at the David Ross Sports Village, Nottingham University, UK. At the conference, Quanta will present a poster that will report on the results of the first 660 treatments completed using SC+ in the UK at Nottingham University Hospitals', Guys and St. Thomas' Hospital and Queen Elizabeth Hospital, Birmingham.